vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and NOODLES & Co (NDLS). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $122.1M, roughly 1.6× NOODLES & Co). NOODLES & Co runs the higher net margin — -7.5% vs -14.6%, a 7.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -4.1%). NOODLES & Co produced more free cash flow last quarter ($-2.8M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -1.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.
AXSM vs NDLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $122.1M |
| Net Profit | $-28.6M | $-9.2M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | -5.2% |
| Net Margin | -14.6% | -7.5% |
| Revenue YoY | 65.0% | -4.1% |
| Net Profit YoY | 61.9% | 32.8% |
| EPS (diluted) | $-0.55 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | $122.1M | ||
| Q2 25 | $150.0M | $123.8M | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | $122.8M | ||
| Q3 24 | $104.8M | $127.4M | ||
| Q2 24 | $87.2M | $121.4M | ||
| Q1 24 | $75.0M | $124.3M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-9.2M | ||
| Q2 25 | $-48.0M | $-9.1M | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | $-6.8M | ||
| Q3 24 | $-64.6M | $-13.6M | ||
| Q2 24 | $-79.3M | $-6.1M | ||
| Q1 24 | $-68.4M | $-6.1M |
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | -5.2% | ||
| Q2 25 | -24.5% | -5.2% | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | -3.9% | ||
| Q3 24 | -59.8% | -9.0% | ||
| Q2 24 | -89.5% | -3.4% | ||
| Q1 24 | -89.7% | -3.7% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -7.5% | ||
| Q2 25 | -32.0% | -7.3% | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | -5.5% | ||
| Q3 24 | -61.7% | -10.7% | ||
| Q2 24 | -91.0% | -5.1% | ||
| Q1 24 | -91.1% | -4.9% |
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | $-0.20 | ||
| Q2 25 | $-0.97 | $-0.20 | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | $-0.15 | ||
| Q3 24 | $-1.34 | $-0.30 | ||
| Q2 24 | $-1.67 | $-0.14 | ||
| Q1 24 | $-1.44 | $-1.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $4.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $-38.9M |
| Total Assets | $689.8M | $280.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | $4.7M | ||
| Q2 25 | $303.0M | $1.4M | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | $3.3M | ||
| Q3 24 | $327.3M | $1.8M | ||
| Q2 24 | $315.7M | $1.3M | ||
| Q1 24 | $331.4M | $3.0M |
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | $-38.9M | ||
| Q2 25 | $73.1M | $-13.9M | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | $3.7M | ||
| Q3 24 | $92.9M | $9.6M | ||
| Q2 24 | $102.9M | $21.9M | ||
| Q1 24 | $144.0M | $27.2M |
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | $280.6M | ||
| Q2 25 | $639.8M | $319.4M | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | $340.5M | ||
| Q3 24 | $561.5M | $346.3M | ||
| Q2 24 | $548.2M | $360.4M | ||
| Q1 24 | $545.7M | $368.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $4.3M |
| Free Cash FlowOCF − Capex | $-18.7M | $-2.8M |
| FCF MarginFCF / Revenue | -9.6% | -2.3% |
| Capex IntensityCapex / Revenue | 0.0% | 5.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $4.3M | ||
| Q2 25 | $-32.4M | $4.0M | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | $5.8M | ||
| Q3 24 | $-18.6M | $4.7M | ||
| Q2 24 | $-30.1M | $7.0M | ||
| Q1 24 | $-53.5M | $164.0K |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $-2.8M | ||
| Q2 25 | $-32.4M | $1.1M | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | $-1.3M | ||
| Q3 24 | $-18.7M | $-4.5M | ||
| Q2 24 | $-30.2M | $-1.6M | ||
| Q1 24 | $-53.6M | $-15.2M |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | -2.3% | ||
| Q2 25 | -21.6% | 0.9% | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | -1.1% | ||
| Q3 24 | -17.9% | -3.5% | ||
| Q2 24 | -34.6% | -1.4% | ||
| Q1 24 | -71.4% | -12.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 5.8% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | 5.8% | ||
| Q3 24 | 0.1% | 7.2% | ||
| Q2 24 | 0.1% | 7.1% | ||
| Q1 24 | 0.1% | 12.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
